Un estudio que evalúa las características de la enfermedad y los resultados en participantes con asma en la práctica clínica habitual (AIRITY)
Estudio transversal y prospectivo híbrido para evaluar las características de los pacientes, la carga de la enfermedad, el control de la enfermedad, los fenotipos, los endotipos y los resultados en un entorno real en pacientes con asma
The main aim of the study to describe the characteristics of participants with asthma across the spectrum of disease severity, including sociodemographic and clinical characteristics, treatment and disease burden, biomarkers, and both disease-specific and generic health-related quality of life.
The study consists of two parts: a cross-sectional study, and a prospective follow-up evaluate changes in disease trajectories in participants with asthma.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Trial Transparency email recommended-Toll free for US & Canada
- Número de teléfono: 6 800-633-1610
- Correo electrónico: Contact-US@sanofi.com
Ubicaciones de estudio
-
-
Bayern (Bavaria)
-
München, Bayern (Bavaria), Alemania, 85039
- Reclutamiento
- Investigational Site Number: 276503
-
-
North Rhine-Westphalia
-
Bonn, North Rhine-Westphalia, Alemania, 53119
- Reclutamiento
- Investigational Site Number: 276505
-
-
Saxony
-
Hohenstein-Ernstthal, Saxony, Alemania, 09337
- Reclutamiento
- Investigational Site Number: 276501
-
-
Schleswig-Holstein
-
Schleswig, Schleswig-Holstein, Alemania, 24837
- Reclutamiento
- Investigational Site Number: 276502
-
-
-
-
Alberta
-
Calgary, Alberta, Canadá, T3R 1W7
- Reclutamiento
- Investigational Site Number: 124203
-
-
Ontario
-
Windsor, Ontario, Canadá, N8X 2G1
- Reclutamiento
- Investigational Site Number: 124201
-
-
Quebec
-
Trois-Rivières, Quebec, Canadá, G8T7A1
- Reclutamiento
- Investigational Site Number: 124204
-
-
-
-
-
Madrid, España, 28034
- Reclutamiento
- Investigational Site Number: 724408
-
-
-
-
Alabama
-
Bessemer, Alabama, Estados Unidos, 35022
- Reclutamiento
- Trinity Clinical Research, LLC - Bessemer - Site Number: 840150
-
-
Arizona
-
Chandler, Arizona, Estados Unidos, 85224
- Retirado
- Chandler Clinical Trials - Site Number: 840106
-
Mesa, Arizona, Estados Unidos, 85206
- Activo, no reclutando
- Del Sol Research Management, LLC - Mesa - Site Number: 840123
-
Scottsdale, Arizona, Estados Unidos, 85254
- Reclutamiento
- Orso Health - Scottsdale - Site Number: 840133
-
Sun City, Arizona, Estados Unidos, 85351
- Activo, no reclutando
- Sun City Clinical Trials - Elite - Site Number: 840120
-
-
California
-
California City, California, Estados Unidos, 91107
- Activo, no reclutando
- FOMAT - Huntington Asthma & Allergy Center - Site Number: 840158
-
La Palma, California, Estados Unidos, 90623
- Activo, no reclutando
- Imax Clinical Trials - Site Number: 840109
-
Los Angeles, California, Estados Unidos, 90017
- Activo, no reclutando
- Downtown LA Research - Site Number: 840161
-
Newport Beach, California, Estados Unidos, 92663
- Activo, no reclutando
- Newport Native MD, Inc. - Site Number: 840101
-
Pasadena, California, Estados Unidos, 91101
- Activo, no reclutando
- Pasadena Clinical Trials - Site Number: 840116
-
Tarzana, California, Estados Unidos, 91356
- Retirado
- Valiance Clinical Research (JPJ Research) - Site Number: 840135
-
Walnut Creek, California, Estados Unidos, 94598
- Activo, no reclutando
- Clinical Research of California - Site Number: 840145
-
-
Florida
-
Altamonte Springs, Florida, Estados Unidos, 32701
- Activo, no reclutando
- Cornerstone Research Institute, LLC - Site Number: 840152
-
Boca Raton, Florida, Estados Unidos, 33431
- Activo, no reclutando
- 3SYNC Research - Boca Raton - Site Number: 840148
-
Brandon, Florida, Estados Unidos, 33511
- Activo, no reclutando
- Meris Clinical Research - Site Number: 840167
-
Greenacres City, Florida, Estados Unidos, 33467
- Activo, no reclutando
- Finlay Medical Research - Site Number: 840107
-
Miami, Florida, Estados Unidos, 33126
- Activo, no reclutando
- EMDA Clinical Research - Site Number: 840113
-
Miami, Florida, Estados Unidos, 33126
- Activo, no reclutando
- Finlay Medical Research - Miami - Site Number: 840110
-
Miami, Florida, Estados Unidos, 33130
- Activo, no reclutando
- Care Research Inc. - Site Number: 840103
-
Miami, Florida, Estados Unidos, 33142
- Activo, no reclutando
- L&A Morales Healthcare, Inc - Site Number: 840102
-
Miami, Florida, Estados Unidos, 33145
- Activo, no reclutando
- MedOne Clinical Research - Site Number: 840122
-
Miami, Florida, Estados Unidos, 33155
- Activo, no reclutando
- D&H National Research Centers INC - Site Number: 840128
-
Miami, Florida, Estados Unidos, 33173
- Activo, no reclutando
- Research Institute Of South Florida - Site Number: 840149
-
Miami, Florida, Estados Unidos, 33174
- Activo, no reclutando
- Valencia Medical & Research Center, Corp - Site Number: 840153
-
Miami, Florida, Estados Unidos, 33186
- Activo, no reclutando
- Correa Research Center, Inc. - Site Number: 840141
-
Miami Gardens, Florida, Estados Unidos, 33014
- Activo, no reclutando
- Pro Care Research Center - Site Number: 840143
-
Miami Lakes, Florida, Estados Unidos, 33014
- Activo, no reclutando
- 3SYNC Research - Miami Lakes - Site Number: 840146
-
Miami Lakes, Florida, Estados Unidos, 33014
- Activo, no reclutando
- Deluxe Health Center - Site Number: 840117
-
Miami Lakes, Florida, Estados Unidos, 33016
- Activo, no reclutando
- MedQuest Translation Sciences, LLC - Site Number: 840162
-
North Miami Beach, Florida, Estados Unidos, 33169
- Activo, no reclutando
- Biscayne Clinical Research - Site Number: 840157
-
Palm Springs, Florida, Estados Unidos, 33406
- Activo, no reclutando
- CTMD Research, Inc - Site Number: 840147
-
Plantation, Florida, Estados Unidos, 33317
- Activo, no reclutando
- Edward Jenner Research Group, LLC - Site Number: 840169
-
Port Saint Lucie, Florida, Estados Unidos, 34986
- Activo, no reclutando
- Mark J. Pamer D.O., LLC - Site Number: 840121
-
Tamarac, Florida, Estados Unidos, 33321
- Activo, no reclutando
- TBC Research Corp - Site Number: 840132
-
Tampa, Florida, Estados Unidos, 33613
- Activo, no reclutando
- Avita Clinical Research - Tampa - Site Number: 840125
-
West Palm Beach, Florida, Estados Unidos, 33409
- Activo, no reclutando
- Palm Beach Medical & Research Center, Inc. - Site Number: 840165
-
-
Georgia
-
Columbus, Georgia, Estados Unidos, 31904
- Activo, no reclutando
- The Allergy Center at Brookstone - Site Number: 840114
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60616
- Activo, no reclutando
- Next Innovation Clinical Research - Chicago - Site Number: 840159
-
-
Kentucky
-
Lexington, Kentucky, Estados Unidos, 40509
- Activo, no reclutando
- Bluegrass Allergy Care - Lexington - Site Number:840112
-
-
Maryland
-
Columbia, Maryland, Estados Unidos, 21045
- Reclutamiento
- Columbia Medical Practice - Site Number: 840172
-
Rockville, Maryland, Estados Unidos, 20854
- Activo, no reclutando
- Velocity Clinical Research - Rockville - Site Number: 840163
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- Reclutamiento
- University of Michigan - Ann Arbor - Site Number: 840140
-
-
Montana
-
Missoula, Montana, Estados Unidos, 59808
- Activo, no reclutando
- Montana Medical Research - Site Number: 840137
-
-
Nebraska
-
Papillion, Nebraska, Estados Unidos, 68046
- Activo, no reclutando
- Primary Clinical Research, LLC - Papillion - Site Number: 840168
-
-
New Jersey
-
Sewell, New Jersey, Estados Unidos, 08080
- Activo, no reclutando
- MedCorps Asthma and Pulmonary Specialists LLC - Sewell - Site Number: 840136
-
-
New York
-
Cortland, New York, Estados Unidos, 13045
- Activo, no reclutando
- Finger Lakes Medical Research, PLLC - Site Number: 840155
-
New Windsor, New York, Estados Unidos, 12553
- Activo, no reclutando
- Mid Hudson Medical Research, PLLC - Site Number: 840139
-
New York, New York, Estados Unidos, 10029
- Activo, no reclutando
- Icahn School of Medicine at Mount Sinai - Center for Advanced Medicine - Site Number: 840119
-
-
North Carolina
-
Asheville, North Carolina, Estados Unidos, 28801
- Activo, no reclutando
- Allergy Partners of Western North Carolina - Site Number: 840131
-
Gastonia, North Carolina, Estados Unidos, 28054-7489
- Activo, no reclutando
- Clinical Research of Gastonia (CRG) - Site Number: 840160
-
Greenville, North Carolina, Estados Unidos, 27834-2849
- Reclutamiento
- East Carolina University Physicians - Pulmonary and Critical Care Medicine - Site Number: 840142
-
-
Ohio
-
Lima, Ohio, Estados Unidos, 45801
- Activo, no reclutando
- NexGen Research - Site Number: 840154
-
Toledo, Ohio, Estados Unidos, 43617
- Activo, no reclutando
- Toledo Institute of Clinical Research Inc - Site Number: 840105
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15241
- Activo, no reclutando
- Allergy and Clinical Immunology Associates - Site Number: 840127
-
-
South Carolina
-
Rock Hill, South Carolina, Estados Unidos, 29732
- Activo, no reclutando
- Clinical Research of Rock Hill - Site Number: 840115
-
-
Tennessee
-
Tennessee City, Tennessee, Estados Unidos, 30909
- Activo, no reclutando
- Allergy Associates, PA dba Allergy, Asthma and Sinus Center - Site Number: 840144
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75235
- Activo, no reclutando
- Southwest Family Medicine Associates - Site Number: 840126
-
El Paso, Texas, Estados Unidos, 79902
- Activo, no reclutando
- El Paso Pulmonary Association (EPPA) - West El Paso - Site Number: 840108
-
Houston, Texas, Estados Unidos, 77090
- Activo, no reclutando
- Lumi Research - Site Number: 840156
-
Houston, Texas, Estados Unidos, 77099
- Activo, no reclutando
- Pioneer Research Solutions - Site Number: 840104
-
Hurst, Texas, Estados Unidos, 76054
- Activo, no reclutando
- Lumi Research - Hurst - Site Number: 840164
-
Tomball, Texas, Estados Unidos, 77081
- Activo, no reclutando
- DM Clinical - Tomball - Site Number: 840130
-
-
Washington
-
Bellingham, Washington, Estados Unidos, 98225
- Activo, no reclutando
- Bellingham Asthma, Allergy & Immunology Clinic - Site Number: 840138
-
-
-
-
Brittany Region
-
Brest, Brittany Region, Francia, 29200
- Reclutamiento
- Investigational Site Number: 250603
-
-
Occitanie
-
Lunel, Occitanie, Francia, 34400
- Reclutamiento
- Investigational Site Number: 250612
-
Toulouse, Occitanie, Francia, 31059
- Reclutamiento
- Investigational Site Number: 250607
-
-
Pays de la Loire Region
-
La Roche-sur-Yon, Pays de la Loire Region, Francia, 85000
- Reclutamiento
- Investigational Site Number: 250613
-
-
Île-de-France Region
-
Argenteuil, Île-de-France Region, Francia, 95100
- Reclutamiento
- Investigational Site Number: 250616
-
Créteil, Île-de-France Region, Francia, 94010
- Reclutamiento
- Investigational Site Number: 250609
-
-
-
-
-
Niigata, Japón
- Reclutamiento
- Investigational Site Number: 392707
-
-
Fukuoka
-
Kitakyushu-Shi, Fukuoka, Japón, 802-0083
- Reclutamiento
- Investigational Site Number: 392705
-
-
Kagawa-ken
-
Takamatsu, Kagawa-ken, Japón, 761-8073
- Reclutamiento
- Investigational Site Number: 392702
-
-
Saga-ken
-
Saga, Saga-ken, Japón, 849-8501
- Reclutamiento
- Investigational Site Number: 392711
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japón, 113-8431
- Reclutamiento
- Investigational Site Number: 392710
-
tabashi City, Tokyo, Japón, 173-8610
- Reclutamiento
- Investigational Site Number: 392709
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Enrollment into Part 1 is planned to achieve a balanced distribution of participants across participating regions, to the extent feasible. In addition, enrollment is intended to include pediatric participants, adolescents, and adults. Enrollment into Part 2 is planned to achieve a balanced distribution of participants across participating regions, to the extent feasible.
Descripción
Inclusion Criteria:
Applicable for Part 1 participants:
- Age 6 years and older, at the time of signing the informed consent
- Physician diagnosis of asthma for at least 12 months
- Existing treatment with low, medium, or high dose ICS and other asthma therapies as reflected in GINA 2-5 steps
- Participant or legally authorized representative (where applicable) has consented to participate
Applicable for Part 2 participants:
- Age 18 years and older, at the time of signing the informed consent.
- Physician diagnosis of asthma for at least 12 months
- Existing treatment with low or medium ICS and other asthma therapies as reflected in GINA 2-4 steps
- Participant or legally authorized representative (where applicable) has consented to participate
- Participants must meet the criteria for at least one of the cohorts below:
A) Asthma control cohorts
- ACQ-5 >= 1.5
- ACQ-5 < 1.5 (B) Type-2 biomarker cohorts
- Elevated T2 biomarkers (B1: Type-2-high cohort)
- Low T2 biomarkers (B2: Type-2-low cohort)
Participants are excluded from the study if any of the following criteria apply (applicable for both Part 1 and Part 2 participants):
- Current diagnosis of chronic obstructive pulmonary disease (COPD) or congestive heart failure
- Participants with moderate/severe cognitive impairment.
- Participants with moderate/severe cardiac disease.
- Participants on immunosuppressive medication for a chronic condition.
- Participation in other interventional and noninterventional clinical study (currently or in the past 3 months)
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Número de grupos/cohortes
Cohortes e Intervenciones
Grupo / CohorteGrupo / Cohorte |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Part-1: Participants With Asthma
Participants receiving treatment with low-, medium-, or high-dose inhaled corticosteroids (ICS) and/or biologic therapies as part of standard of care (SoC) for the management of asthma in routine clinical practice. |
Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration. Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration. |
|
Part-2: A1- Uncontrolled Asthma Cohort
Participants receiving SoC with Asthma Control Questionnaire-5 (ACQ-5) threshold of greater than or equal to (>=)1.5 |
Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration. Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration. |
|
Part-2: A2- Controlled Asthma Cohort
Participants receiving SoC with Asthma Control Questionnaire-5 (ACQ-5) threshold of less than (<)1.5 |
Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration. Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration. |
|
Part-2: B1- Type-2 (T2) High Asthma Cohort
Participants receiving SoC with elevated T2 biomarkers |
Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration. Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration. |
|
Part-2: B2- Type-2 Low Asthma Cohort
Participants receiving SoC with low T2 biomarkers |
Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration. Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Part 1: Descriptive Characterization of Participants With Asthma Across the Spectrum of Severities
Periodo de tiempo: Part 1: At baseline
|
Descriptive Statistical Analyses may include sociodemographic and clinical characteristics, comorbidities, exacerbation history, medication burden, biomarkers and lung function. |
Part 1: At baseline
|
|
Part 1: ACQ-5 Scores to Evaluate Characteristics of Participants With Asthma
Periodo de tiempo: Part 1: At baseline
|
ACQ-5 is a 5-question survey. The five ACQ-5 questions are scored on a 6-point scale (0 = good control, 6 = poor control), and the overall score is the mean of the five responses. Participant's scores are then classified into three prescribed groups as having well-controlled asthma (score ≤ 0.75); partially controlled asthma (score 0.75-1.5), or not well controlled asthma (score >1.5). A change in ACQ-5 score of 0.5 is considered the minimal clinically important difference (MCID) |
Part 1: At baseline
|
|
Part 1: Mini-Asthma Quality of Life Questionnaire (Mini-AQLQ) Scores to Evaluate Characteristics of Participants With Asthma
Periodo de tiempo: Part 1: At baseline
|
The Asthma Quality of Life Questionnaire (AQLQ) includes 32 items, The mini-AQLQ is a reduced version of the AQLQ which includes 15 items. The questions correspond to 4 dimensions of health: symptoms (5 items), limitation of usual activities (4 items), emotional function (3 items) and environmental stimuli (3 items). The response options for each item are on an equidistant scale of 7 points, where 1 corresponds to the maximum disability and 7 to the absence of disability. Higher scores indicating better quality of life (less impairment) and lower scores indicating worse quality of life (greater impairment). |
Part 1: At baseline
|
|
Part 1: Physician Global Assessment of Asthma Severity and Symptom Control
Periodo de tiempo: Part 1: At baseline
|
Asthma severity, asthma control, and comorbidity will be assessed using three global impression of severity items: Physician Global Impression of Severity (PhGIS) - asthma severity. PhGIS - asthma control, and PhGIS - comorbidity. |
Part 1: At baseline
|
|
Part 2: Descriptive Statistical Analysis of Difference in Asthma Symptom Control (ACQ-5) Between Part 2 Cohorts A1 and A2
Periodo de tiempo: Part 2: At Weeks 52 and 104
|
Data on participant's asthma symptoms and control will be collected via the ACQ-5, 5-question survey. The five ACQ-5 questions are scored on a 6-point scale (0 = good control, 6 = poor control), and the overall score is the mean of the five responses. Participant's scores are then classified into three prescribed groups as having well-controlled asthma (score <=0.75); partially controlled asthma (score 0.75-1.5), or not well controlled asthma (score >1.5). A change in ACQ-5 score of 0.5 is considered the MCID. |
Part 2: At Weeks 52 and 104
|
|
Part 2: Number of Participants Analyzed with Treatment Utilization Pattern between Part 2 Cohorts A1 and A2
Periodo de tiempo: Part 2: At Weeks 52 and 104
|
Treatment utilization will include systemic corticosteroids (SCS), ICS, and short-acting beta agonists (SABA). Number of participants with various treatment utilization pattern will be assessed and reported. |
Part 2: At Weeks 52 and 104
|
|
Part 2: Descriptive Statistical Analysis of Difference in Change in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV₁) between Part 2 Cohorts B1 and Cohort B2
Periodo de tiempo: Part-2: At Weeks 52 and 104
|
Pre-BD FEV₁ is the forced expiratory volume in 1 second measured by spirometry prior to bronchodilator administration. |
Part-2: At Weeks 52 and 104
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Parte 1: Número de participantes caracterizados por sus datos demográficos y características clínicas
Periodo de tiempo: Parte 1: Desde 12 meses antes de la inscripción en el estudio
|
Parte 1: Desde 12 meses antes de la inscripción en el estudio
|
|
|
Parte 1: Número de participantes caracterizados por su carga de enfermedad, estado de salud, experiencias de tratamiento
Periodo de tiempo: Parte 1: Desde 12 meses antes de la inscripción en el estudio
|
Parte 1: Desde 12 meses antes de la inscripción en el estudio
|
|
|
Parte 1: Número de Participantes Caracterizados por el Uso de Medicación
Periodo de tiempo: Parte 1: Desde 12 meses antes de la inscripción al estudio
|
Parte 1: Desde 12 meses antes de la inscripción al estudio
|
|
|
Parte 1: Número de participantes caracterizados por su estilo de vida e influencias ambientales
Periodo de tiempo: Parte 1: Desde 12 meses antes de la inscripción al estudio
|
Parte 1: Desde 12 meses antes de la inscripción al estudio
|
|
|
Parte 1: Número de participantes caracterizados por el uso de corticosteroides inhalados y sistémicos
Periodo de tiempo: Parte 1: Desde 12 meses antes de la inscripción al estudio
|
Parte 1: Desde 12 meses antes de la inscripción al estudio
|
|
|
Parte 1: Número de participantes caracterizados por Utilización de Recursos Sanitarios (URS)
Periodo de tiempo: Parte 1: Desde 12 meses antes de la inscripción al estudio
|
Parte 1: Desde 12 meses antes de la inscripción al estudio
|
|
|
Parte 2: Caracterización descriptiva que incluye datos sociodemográficos, características de la enfermedad e historial de tratamiento.
Periodo de tiempo: Parte 2: Al inicio del estudio
|
Parte 2: Al inicio del estudio
|
|
|
Parte 2: Tasas de Exacerbación Anualizadas en las Semanas 52 y 104
Periodo de tiempo: Parte 2: En las semanas 52 y 104
|
Parte 2: En las semanas 52 y 104
|
|
|
Parte 2: Número de participantes analizados para cambios en la carga de corticosteroides inhalados y sistémicos
Periodo de tiempo: Parte 2: Desde el inicio hasta la semana 104
|
Parte 2: Desde el inicio hasta la semana 104
|
|
|
Parte 2: Cambios en el nivel del biomarcador
Periodo de tiempo: Parte 2: En las semanas 52 y 104
|
Parte 2: En las semanas 52 y 104
|
|
|
Part 1: Physician-Reported Outcomes to Characterize Physician Perspectives
Periodo de tiempo: Part 1: From 12 months prior to study enrollment
|
The treatment preferences for participant profiles, an assessment of perceived disease burden on participants, an evaluation of barriers to optimal treatment, and treatment adherence and persistence will be collected from the main treating physician. |
Part 1: From 12 months prior to study enrollment
|
|
Part 1: Change From Baseline in Patient Global Impression of Severity (PGIS) Score
Periodo de tiempo: Part 1: From 12 months prior to study enrollment
|
The PGIS is a single question asking the participant to rate their severity and symptom control. The PGIS is a 5-point ordinal scale ranging from 1 (No symptoms) to 5 (Very severe symptoms). Higher scores indicate greater symptom severity. |
Part 1: From 12 months prior to study enrollment
|
|
Part 1: Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Score
Periodo de tiempo: Part 1: From 12 months prior to study enrollment
|
The WPAI-Asthma is an Asthma-specific, patient-reported measure of work absenteeism, work presenteeism (reduced productivity while working due to illness), total work productivity loss (absenteeism plus presenteeism), and overall activity impairment over the prior 7 days. The WPAI-Asthma questionnaire score represents the percentage of impairment, from 0 to 100%. Higher scores represent greater impairment and less productivity. |
Part 1: From 12 months prior to study enrollment
|
|
Part 2: Changes From Baseline to Week 104 in Pre and Post Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Periodo de tiempo: Part 2: From baseline to week 52 and week 104
|
FEV1 will be measured in Liters. Change from baseline: mean of (value of observed FEV1 at treatment duration minus baseline value). |
Part 2: From baseline to week 52 and week 104
|
|
Part 2: Number of Participants With Significant Changes in Asthma Treatment Patterns at Week 52 and Week 104
Periodo de tiempo: Part 2: From baseline to week 52 and week 104
|
Changes in treatment patterns including use of SCS, ICS, other asthma therapies, and rescue medication. Treatment escalation (for example [e.g.], ICS dose changes, addition of asthma therapies, or biologic prescription), treatment adherence, and treatment persistence will be assessed from baseline to Week 52 and Week 104 in participants with Asthma. |
Part 2: From baseline to week 52 and week 104
|
|
Part 2: Changes in Physician Global Assessment of Asthma Severity, Symptom Control and Comorbidities (PhGIS)
Periodo de tiempo: Part 2: From baseline to week 52 and week 104
|
Asthma severity, asthma control, and comorbidity will be assessed using three global impression of severity items: PhGIS - asthma severity. PhGIS - asthma control, and PhGIS - comorbidity. |
Part 2: From baseline to week 52 and week 104
|
|
Part 2: Number of Participants With Comorbidities and Burden of Comorbidities Based on the Participant Survey Using the PGIS scale
Periodo de tiempo: Part 2: At Weeks 52 and 104
|
The PGIS is a single question asking the participant to rate their severity and symptom control. The PGIS is a 5-point ordinal scale ranging from 1 (No symptoms) to 5 (Very severe symptoms). Higher scores indicate greater symptom severity. |
Part 2: At Weeks 52 and 104
|
|
Part 2: Number of Participants With Comorbidities and Burden of Comorbidities Based on the Physician Survey Using the PhGIS Scale
Periodo de tiempo: Part 2: At Weeks 52 and 104
|
Asthma severity, asthma control, and comorbidity will be assessed using three global impression of severity items: PhGIS - asthma severity. PhGIS - asthma control, and PhGIS - comorbidity. |
Part 2: At Weeks 52 and 104
|
|
Part 2: Changes in Physician-reported HCRU (Hospitalizations, Outpatient and Emergency Visits)
Periodo de tiempo: Part 2: From baseline to week 52 and week 104
|
Data about HCRU associated with medical encounters will be collected by physicians from medical records. The data collected will include setting, department, type of specialist, the reasons and duration of hospitalizations, outpatient and emergency room (ER) visits. |
Part 2: From baseline to week 52 and week 104
|
|
Part 2: Changes in Patient-Reported Outcomes to Characterize Disease Evolution
Periodo de tiempo: Part 2: At Weeks 52 and 104
|
PROs used will include but not limited to ACQ-5, mini-AQLQ. ACQ-5 questions are scored on a 6-point scale (0 = good control, 6 = poor control), Mean of the five responses is the overall score. Scores are then classified into three groups as having well-controlled asthma (score <= 0.75); partially controlled asthma (score 0.75-1.5), or not well controlled asthma (score >1.5). AQLQ includes 32 items, The mini-AQLQ is a reduced version of the AQLQ which includes 15 items. The questions correspond to 4 dimensions of health: symptoms (5 items), limitation of usual activities (4 items), emotional function (3 items) and environmental stimuli (3 items). The response options for each item are on an equidistant scale of 7 points, where 1 corresponds to the maximum disability and 7 to the absence of disability. |
Part 2: At Weeks 52 and 104
|
|
Part 2: Changes in Participant Survey Response
Periodo de tiempo: Part 2: From baseline to week 52 and week 104
|
Participant survey collecting demographics, clinical characteristics, disease burden, health status, treatment experiences, medication use and burden, work and school impacts, lifestyle and environmental influences, impacts on daily life, PGIS for each comorbidity and burden of comorbidities, inhaled and systemic corticosteroid burden (frequency of use, routes of administration, treatment satisfaction), and HCRU office visits, hospitalizations, outpatient and emergency visits will be collected from medical records. |
Part 2: From baseline to week 52 and week 104
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- PIR21191
- 2025-524916-13-00 (Ctis)
- U1111-1336-5183 (Identificador de registro: ICTRP)
- 2025 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .